 Shawn McCandless
Concepts (384)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 12 | 2020 | 152 | 2.490 |
Why?
| | Urea Cycle Disorders, Inborn | 16 | 2020 | 22 | 2.140 |
Why?
| | Prader-Willi Syndrome | 7 | 2023 | 25 | 2.080 |
Why?
| | Phenylbutyrates | 12 | 2020 | 21 | 1.310 |
Why?
| | Metabolism, Inborn Errors | 6 | 2021 | 39 | 1.170 |
Why?
| | Glycerol | 11 | 2020 | 84 | 1.160 |
Why?
| | Abnormalities, Multiple | 6 | 2013 | 178 | 0.870 |
Why?
| | Phenylketonurias | 3 | 2023 | 11 | 0.810 |
Why?
| | Ammonia | 9 | 2020 | 56 | 0.800 |
Why?
| | Infant, Newborn | 28 | 2022 | 5043 | 0.750 |
Why?
| | Glutamine | 9 | 2018 | 91 | 0.700 |
Why?
| | Hyperphagia | 3 | 2023 | 28 | 0.670 |
Why?
| | Chromosome Deletion | 4 | 2010 | 95 | 0.650 |
Why?
| | Galactosemias | 1 | 2019 | 8 | 0.640 |
Why?
| | Aminopeptidases | 1 | 2017 | 9 | 0.580 |
Why?
| | Cinnamates | 1 | 2017 | 10 | 0.580 |
Why?
| | Cyclohexanes | 1 | 2017 | 22 | 0.580 |
Why?
| | Appetite Depressants | 1 | 2017 | 18 | 0.580 |
Why?
| | Epoxy Compounds | 1 | 2017 | 31 | 0.580 |
Why?
| | Sesquiterpenes | 1 | 2017 | 51 | 0.560 |
Why?
| | Acidosis | 1 | 2017 | 88 | 0.550 |
Why?
| | Protease Inhibitors | 1 | 2017 | 97 | 0.550 |
Why?
| | Genetic Testing | 4 | 2023 | 379 | 0.550 |
Why?
| | Lysosomal Storage Diseases | 1 | 2015 | 4 | 0.510 |
Why?
| | Public Health | 1 | 2020 | 433 | 0.510 |
Why?
| | Glycoproteins | 1 | 2017 | 304 | 0.500 |
Why?
| | Hyperammonemia | 4 | 2020 | 15 | 0.470 |
Why?
| | Infant | 24 | 2023 | 7959 | 0.460 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 96 | 0.460 |
Why?
| | Child, Preschool | 26 | 2022 | 9108 | 0.440 |
Why?
| | Consanguinity | 1 | 2013 | 46 | 0.430 |
Why?
| | Lipid Metabolism, Inborn Errors | 1 | 2012 | 16 | 0.420 |
Why?
| | Hazardous Substances | 1 | 2012 | 9 | 0.410 |
Why?
| | Obesity | 2 | 2017 | 2507 | 0.410 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 740 | 0.390 |
Why?
| | Amino Acids | 1 | 2015 | 448 | 0.390 |
Why?
| | Humans | 70 | 2023 | 114623 | 0.370 |
Why?
| | Phenylalanine | 4 | 2023 | 57 | 0.350 |
Why?
| | Rare Diseases | 5 | 2019 | 89 | 0.330 |
Why?
| | Child | 29 | 2023 | 18404 | 0.330 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 975 | 0.310 |
Why?
| | Phenylacetates | 4 | 2020 | 9 | 0.300 |
Why?
| | Adolescent | 21 | 2023 | 17831 | 0.290 |
Why?
| | Female | 41 | 2023 | 59466 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 1879 | 0.280 |
Why?
| | Feeding Behavior | 1 | 2012 | 574 | 0.280 |
Why?
| | Male | 38 | 2021 | 55554 | 0.280 |
Why?
| | Young Adult | 14 | 2022 | 10455 | 0.260 |
Why?
| | Mutation | 8 | 2019 | 3344 | 0.250 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2005 | 49 | 0.240 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 31 | 0.240 |
Why?
| | Infant Formula | 2 | 2018 | 74 | 0.240 |
Why?
| | Methionine | 2 | 2021 | 144 | 0.240 |
Why?
| | Trisomy | 1 | 2005 | 68 | 0.230 |
Why?
| | Neutropenia | 2 | 2022 | 125 | 0.230 |
Why?
| | False Positive Reactions | 2 | 2015 | 109 | 0.220 |
Why?
| | Vitamin B 12 | 2 | 2021 | 115 | 0.220 |
Why?
| | Growth Disorders | 2 | 2019 | 77 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2003 | 36 | 0.220 |
Why?
| | Face | 2 | 2020 | 164 | 0.210 |
Why?
| | Phenotype | 7 | 2019 | 2796 | 0.210 |
Why?
| | Mass Spectrometry | 3 | 2004 | 633 | 0.210 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2022 | 5 | 0.200 |
Why?
| | Cost of Illness | 1 | 2003 | 254 | 0.190 |
Why?
| | Leukodystrophy, Metachromatic | 1 | 2001 | 3 | 0.190 |
Why?
| | Strabismus | 1 | 2021 | 26 | 0.190 |
Why?
| | Metabolism | 1 | 2021 | 35 | 0.190 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2000 | 18 | 0.180 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 2 | 2021 | 19 | 0.180 |
Why?
| | Prenatal Care | 1 | 2023 | 253 | 0.180 |
Why?
| | Double-Blind Method | 4 | 2023 | 1660 | 0.180 |
Why?
| | Acyl-CoA Dehydrogenase | 3 | 2012 | 8 | 0.180 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 480 | 0.180 |
Why?
| | Adult | 17 | 2022 | 30528 | 0.170 |
Why?
| | Alleles | 3 | 2019 | 789 | 0.170 |
Why?
| | Orphan Drug Production | 1 | 2019 | 6 | 0.170 |
Why?
| | Registries | 4 | 2021 | 1767 | 0.170 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 364 | 0.160 |
Why?
| | Mental Status and Dementia Tests | 1 | 2019 | 21 | 0.160 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2019 | 74 | 0.160 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1691 | 0.160 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 31 | 0.160 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 59 | 0.160 |
Why?
| | DNA Polymerase II | 1 | 2018 | 37 | 0.160 |
Why?
| | Osteochondrodysplasias | 1 | 2018 | 15 | 0.160 |
Why?
| | Fetus | 1 | 2023 | 699 | 0.160 |
Why?
| | Goldenhar Syndrome | 1 | 1998 | 4 | 0.160 |
Why?
| | Eye Abnormalities | 1 | 1998 | 10 | 0.160 |
Why?
| | Skin Abnormalities | 1 | 1998 | 10 | 0.160 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1342 | 0.160 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 26 | 0.150 |
Why?
| | Lipase | 1 | 2018 | 55 | 0.150 |
Why?
| | Endpoint Determination | 1 | 2018 | 68 | 0.150 |
Why?
| | Exome | 1 | 2019 | 200 | 0.150 |
Why?
| | Fructose Intolerance | 1 | 2018 | 3 | 0.150 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2018 | 7 | 0.150 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1998 | 38 | 0.150 |
Why?
| | Prodrugs | 1 | 2018 | 42 | 0.150 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 48 | 0.150 |
Why?
| | Pyruvate Dehydrogenase Complex | 1 | 2017 | 8 | 0.150 |
Why?
| | Methionyl Aminopeptidases | 1 | 2017 | 1 | 0.150 |
Why?
| | Pyruvate Dehydrogenase Complex Deficiency Disease | 1 | 2017 | 7 | 0.150 |
Why?
| | Body Mass Index | 2 | 2017 | 1956 | 0.150 |
Why?
| | Enzyme Assays | 1 | 2017 | 21 | 0.150 |
Why?
| | Parents | 3 | 2020 | 1186 | 0.150 |
Why?
| | Early Termination of Clinical Trials | 1 | 2017 | 14 | 0.150 |
Why?
| | Ketones | 1 | 2017 | 44 | 0.150 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 68 | 0.140 |
Why?
| | Pediatricians | 1 | 2019 | 122 | 0.140 |
Why?
| | Syndrome | 4 | 2020 | 333 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 510 | 0.140 |
Why?
| | Glutaryl-CoA Dehydrogenase | 1 | 2016 | 4 | 0.140 |
Why?
| | United States | 6 | 2020 | 12176 | 0.140 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 122 | 0.140 |
Why?
| | Patient Preference | 1 | 2018 | 167 | 0.140 |
Why?
| | Brain Diseases, Metabolic | 1 | 2016 | 7 | 0.140 |
Why?
| | Prevalence | 2 | 2012 | 2249 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 988 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1796 | 0.130 |
Why?
| | Indians, North American | 1 | 2001 | 570 | 0.130 |
Why?
| | Venous Thrombosis | 1 | 2017 | 140 | 0.130 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2015 | 66 | 0.120 |
Why?
| | Mosaicism | 2 | 2005 | 60 | 0.120 |
Why?
| | Fibroblasts | 2 | 2017 | 837 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2014 | 65 | 0.110 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2013 | 8 | 0.110 |
Why?
| | Genotype | 1 | 2019 | 1760 | 0.110 |
Why?
| | Hepatic Encephalopathy | 1 | 2013 | 19 | 0.110 |
Why?
| | Fetal Growth Retardation | 1 | 2018 | 467 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1842 | 0.110 |
Why?
| | Rape | 1 | 2013 | 36 | 0.110 |
Why?
| | Ubiquinone | 1 | 2012 | 21 | 0.100 |
Why?
| | Drug Substitution | 1 | 2013 | 46 | 0.100 |
Why?
| | Weight Loss | 1 | 2017 | 641 | 0.100 |
Why?
| | Siblings | 1 | 2013 | 221 | 0.100 |
Why?
| | Intellectual Disability | 3 | 2019 | 128 | 0.100 |
Why?
| | Caregivers | 1 | 2018 | 717 | 0.100 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 77 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2537 | 0.100 |
Why?
| | Carnitine | 2 | 2003 | 62 | 0.100 |
Why?
| | Self Report | 1 | 2015 | 696 | 0.100 |
Why?
| | Biomarkers | 3 | 2016 | 3408 | 0.100 |
Why?
| | Infant, Premature | 1 | 2015 | 476 | 0.100 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 4620 | 0.090 |
Why?
| | Heart Defects, Congenital | 3 | 2010 | 671 | 0.090 |
Why?
| | Urinary Tract | 1 | 1991 | 36 | 0.090 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2010 | 22 | 0.090 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2021 | 16 | 0.090 |
Why?
| | Middle Aged | 10 | 2021 | 26719 | 0.090 |
Why?
| | Ectodermal Dysplasia | 1 | 2010 | 15 | 0.090 |
Why?
| | Diaphragm | 1 | 2010 | 33 | 0.090 |
Why?
| | Homocysteine | 2 | 2021 | 136 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1466 | 0.090 |
Why?
| | Mental Disorders | 1 | 1998 | 892 | 0.090 |
Why?
| | Diseases in Twins | 1 | 1991 | 174 | 0.090 |
Why?
| | Liver | 3 | 2013 | 1634 | 0.090 |
Why?
| | Vaginal Diseases | 1 | 2010 | 17 | 0.090 |
Why?
| | Risk | 1 | 2012 | 812 | 0.080 |
Why?
| | Chromosome Banding | 2 | 2010 | 21 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 99 | 0.080 |
Why?
| | Cohort Studies | 2 | 2019 | 4894 | 0.080 |
Why?
| | alpha-Glucosidases | 1 | 2009 | 9 | 0.080 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2009 | 7 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 93 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4411 | 0.080 |
Why?
| | Ultrasonography, Prenatal | 1 | 2010 | 235 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 180 | 0.080 |
Why?
| | Overweight | 1 | 2012 | 471 | 0.080 |
Why?
| | Gene Frequency | 2 | 2016 | 477 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2010 | 381 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2014 | 440 | 0.070 |
Why?
| | Iduronate Sulfatase | 1 | 2006 | 1 | 0.070 |
Why?
| | Mucopolysaccharidosis II | 1 | 2006 | 2 | 0.070 |
Why?
| | Sex Factors | 1 | 2012 | 1715 | 0.070 |
Why?
| | Time Factors | 2 | 2015 | 6112 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 290 | 0.070 |
Why?
| | Brain | 1 | 1998 | 2371 | 0.070 |
Why?
| | Muscle, Skeletal | 2 | 2013 | 1472 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2022 | 12542 | 0.070 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 309 | 0.070 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 162 | 0.060 |
Why?
| | Diet | 1 | 2012 | 1080 | 0.060 |
Why?
| | Karyotyping | 1 | 2005 | 102 | 0.060 |
Why?
| | Fragile X Syndrome | 1 | 2005 | 64 | 0.060 |
Why?
| | Pregnancy | 4 | 2023 | 5517 | 0.060 |
Why?
| | Anxiety | 2 | 2023 | 840 | 0.060 |
Why?
| | Chromosome Disorders | 1 | 2005 | 35 | 0.060 |
Why?
| | Quality of Life | 1 | 2015 | 2353 | 0.060 |
Why?
| | Disease Management | 2 | 2019 | 560 | 0.060 |
Why?
| | Microcephaly | 1 | 2005 | 51 | 0.060 |
Why?
| | Fatal Outcome | 2 | 2010 | 284 | 0.060 |
Why?
| | Neuropsychological Tests | 3 | 2019 | 927 | 0.060 |
Why?
| | Lymphocytes | 3 | 2017 | 330 | 0.060 |
Why?
| | Radiography | 2 | 2010 | 812 | 0.060 |
Why?
| | Heterozygote | 2 | 2001 | 251 | 0.060 |
Why?
| | Gene Deletion | 1 | 2005 | 356 | 0.060 |
Why?
| | X Chromosome | 2 | 2000 | 47 | 0.060 |
Why?
| | Hyperhomocysteinemia | 1 | 2003 | 24 | 0.050 |
Why?
| | Food, Fortified | 1 | 2003 | 36 | 0.050 |
Why?
| | Carbon-Carbon Ligases | 1 | 2003 | 2 | 0.050 |
Why?
| | Cough | 2 | 2017 | 107 | 0.050 |
Why?
| | Pedigree | 2 | 2001 | 460 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 238 | 0.050 |
Why?
| | Oxytocin | 1 | 2023 | 45 | 0.050 |
Why?
| | Infant Food | 1 | 2003 | 63 | 0.050 |
Why?
| | RNA-Binding Proteins | 1 | 2005 | 344 | 0.050 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2022 | 71 | 0.050 |
Why?
| | Glucosides | 1 | 2022 | 36 | 0.050 |
Why?
| | Workflow | 1 | 2023 | 133 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 562 | 0.050 |
Why?
| | Developmental Disabilities | 1 | 2005 | 237 | 0.050 |
Why?
| | Benzhydryl Compounds | 1 | 2022 | 60 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 529 | 0.050 |
Why?
| | Founder Effect | 1 | 2001 | 13 | 0.050 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2001 | 3 | 0.050 |
Why?
| | Homozygote | 2 | 2018 | 187 | 0.050 |
Why?
| | History, 19th Century | 1 | 2001 | 54 | 0.050 |
Why?
| | United States Indian Health Service | 1 | 2001 | 42 | 0.050 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 33 | 0.050 |
Why?
| | Hand Deformities, Congenital | 1 | 2000 | 8 | 0.050 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2000 | 21 | 0.050 |
Why?
| | Facies | 1 | 2000 | 20 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2021 | 124 | 0.040 |
Why?
| | Warfare | 1 | 2001 | 75 | 0.040 |
Why?
| | Betaine | 1 | 2000 | 63 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 217 | 0.040 |
Why?
| | History, 20th Century | 1 | 2001 | 264 | 0.040 |
Why?
| | Methyltransferases | 1 | 2000 | 61 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4405 | 0.040 |
Why?
| | Vitamins | 1 | 2021 | 151 | 0.040 |
Why?
| | Nucleocytoplasmic Transport Proteins | 1 | 2019 | 6 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2311 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2001 | 293 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 445 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2635 | 0.040 |
Why?
| | Length of Stay | 1 | 2003 | 962 | 0.040 |
Why?
| | Adrenoleukodystrophy | 1 | 1999 | 4 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2019 | 43 | 0.040 |
Why?
| | Angelman Syndrome | 1 | 1999 | 8 | 0.040 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2019 | 6 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2018 | 5 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2019 | 106 | 0.040 |
Why?
| | Genomic Imprinting | 1 | 1999 | 32 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 276 | 0.040 |
Why?
| | Executive Function | 1 | 2023 | 379 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 287 | 0.040 |
Why?
| | Urea | 1 | 2019 | 67 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1999 | 56 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 70 | 0.040 |
Why?
| | Cleft Lip | 1 | 1998 | 31 | 0.040 |
Why?
| | Canada | 1 | 2019 | 322 | 0.040 |
Why?
| | Drug Industry | 1 | 2019 | 103 | 0.040 |
Why?
| | Europe | 1 | 2019 | 334 | 0.040 |
Why?
| | North America | 1 | 2019 | 256 | 0.040 |
Why?
| | Cleft Palate | 1 | 1998 | 45 | 0.040 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2017 | 3 | 0.040 |
Why?
| | Acidosis, Lactic | 1 | 2017 | 27 | 0.040 |
Why?
| | Nitrogen | 1 | 2018 | 143 | 0.040 |
Why?
| | Lipids | 1 | 2021 | 580 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 1997 | 271 | 0.040 |
Why?
| | Skull | 1 | 1998 | 119 | 0.040 |
Why?
| | DNA Replication | 1 | 2018 | 202 | 0.040 |
Why?
| | Global Health | 1 | 2019 | 287 | 0.040 |
Why?
| | Biochemistry | 1 | 2017 | 40 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2020 | 374 | 0.040 |
Why?
| | Prospective Studies | 2 | 2019 | 6217 | 0.040 |
Why?
| | Recombinant Proteins | 3 | 2006 | 1230 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1998 | 131 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 384 | 0.030 |
Why?
| | Glutarates | 1 | 2016 | 6 | 0.030 |
Why?
| | Cocaine | 1 | 1998 | 153 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 896 | 0.030 |
Why?
| | Fever | 1 | 2017 | 280 | 0.030 |
Why?
| | Child Behavior | 1 | 1998 | 219 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 530 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1317 | 0.030 |
Why?
| | Cognition Disorders | 1 | 1999 | 476 | 0.030 |
Why?
| | Primary Health Care | 1 | 2004 | 1512 | 0.030 |
Why?
| | North Carolina | 2 | 2006 | 97 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 240 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2023 | 9084 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 411 | 0.030 |
Why?
| | Immunoglobulin G | 2 | 2009 | 770 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 1998 | 429 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2785 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 979 | 0.030 |
Why?
| | Enzyme Stability | 2 | 2004 | 62 | 0.030 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.030 |
Why?
| | Alcohol Drinking | 1 | 1998 | 651 | 0.030 |
Why?
| | DNA Mutational Analysis | 2 | 2005 | 372 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2019 | 707 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 345 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1528 | 0.020 |
Why?
| | DNA | 2 | 2010 | 1352 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 1991 | 16 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 2894 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2010 | 16 | 0.020 |
Why?
| | Chromosome Breakage | 1 | 2010 | 21 | 0.020 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2010 | 18 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 28 | 0.020 |
Why?
| | Muscle Hypotonia | 1 | 2010 | 31 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 718 | 0.020 |
Why?
| | Colpotomy | 1 | 2010 | 2 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 1991 | 210 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3328 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 224 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 3881 | 0.020 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 54 | 0.020 |
Why?
| | Pilot Projects | 2 | 2006 | 1372 | 0.020 |
Why?
| | Escherichia coli | 2 | 2004 | 720 | 0.020 |
Why?
| | Tracheostomy | 1 | 2010 | 101 | 0.020 |
Why?
| | Aged | 2 | 2018 | 19061 | 0.020 |
Why?
| | Glycogen | 1 | 2009 | 51 | 0.020 |
Why?
| | Vagina | 1 | 2010 | 146 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1214 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 180 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6344 | 0.020 |
Why?
| | Skin Diseases | 1 | 2009 | 122 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2010 | 529 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 928 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 797 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 585 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 811 | 0.020 |
Why?
| | Glycosaminoglycans | 1 | 2006 | 79 | 0.020 |
Why?
| | Joints | 1 | 2006 | 84 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 553 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2006 | 48 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2006 | 31 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 371 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 68 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2006 | 522 | 0.020 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2005 | 51 | 0.020 |
Why?
| | Spleen | 1 | 2006 | 487 | 0.020 |
Why?
| | Safety | 1 | 2006 | 297 | 0.020 |
Why?
| | Myristic Acid | 1 | 2004 | 10 | 0.010 |
Why?
| | Body Weight | 1 | 2009 | 868 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1879 | 0.010 |
Why?
| | Histidine | 1 | 2004 | 57 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2004 | 135 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2004 | 67 | 0.010 |
Why?
| | Tyrosine | 1 | 2004 | 214 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 262 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 502 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2387 | 0.010 |
Why?
| | Fatty Acids | 1 | 2006 | 381 | 0.010 |
Why?
| | Acids | 1 | 2003 | 16 | 0.010 |
Why?
| | Brain Edema | 1 | 2003 | 60 | 0.010 |
Why?
| | Glutamic Acid | 1 | 2004 | 211 | 0.010 |
Why?
| | Lysine | 1 | 2004 | 242 | 0.010 |
Why?
| | Chaperonin 10 | 1 | 2001 | 2 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2003 | 133 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2114 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2001 | 12 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2004 | 923 | 0.010 |
Why?
| | Prion Proteins | 1 | 2000 | 4 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2000 | 24 | 0.010 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2000 | 11 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2000 | 52 | 0.010 |
Why?
| | Prions | 1 | 2000 | 33 | 0.010 |
Why?
| | Exons | 1 | 2001 | 302 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 353 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 119 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2097 | 0.010 |
Why?
| | Amyloid | 1 | 2000 | 80 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 239 | 0.010 |
Why?
| | Models, Molecular | 1 | 2004 | 1369 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2000 | 487 | 0.010 |
Why?
| | Haplotypes | 1 | 2001 | 448 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1999 | 52 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 565 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1999 | 167 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 294 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2000 | 723 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 1982 | 0.010 |
Why?
| | Rats | 1 | 2004 | 4958 | 0.010 |
Why?
| | Social Behavior | 1 | 1999 | 267 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 993 | 0.010 |
Why?
| | Animals | 3 | 2004 | 31694 | 0.010 |
Why?
| | DNA Methylation | 1 | 1999 | 495 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 2762 | 0.010 |
Why?
| | Mice | 2 | 2000 | 14860 | 0.010 |
Why?
| | Genetic Variation | 1 | 1997 | 870 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 3039 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2380 | 0.010 |
Why?
|
|
McCandless's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|